Over the next four years, Illumina and Trivitron intend to develop and distribute a suite of standardised, commercial IVD assays to deliver an effective and non-invasive way of diagnosing cancers, determining infectious pathogens, and identifying prenatal diseases. Over the next four years, Illumina and Trivitron intend to develop and distribute a suite of standardised, commercial IVD assays to deliver an effective and non-invasive way of diagnosing cancers, determining infectious pathogens, and identifying prenatal diseases.